Last Updated on October 6, 2024 by The Health Master
New Delhi: The U.S. Food and Drug Administration (USFDA) approved Cidara Therapeutics Inc’s drug, rezafungin, to treat a group of severe fungal infections that are most commonly faced by hospitalized patients, the company said.
USFDA approved the drug to treat the infections in adult patients with limited or no alternative treatment options, in line with recommendations made in January by the agency’s panel of outside experts, who voted 14-1 in favor of the drug’s use.
Rezafungin, branded as Rezzayo, is dosed once a week for patients, who usually have to depend on daily doses as part of current standard-of-care treatment.
Antibiotics maker Melinta Therapeutics, which has commercialization rights for the drug in the U.S. market, plans to make rezafungin available this summer.
The company will announce the drug’s list price closer to that time, Melinta CEO Christine Miller told Reuters before the USFDA decision.
Rezzayo belongs to a class of drugs known as echinocandin, which are recommended as first-line therapy for fungal infections by the Infectious Diseases Society of America.
In a late-stage study, the drug showed it was no worse compared with the current standard of care, according to Cidara.
There was a blockbuster potential for the drug to treat the “silent killer” fungal infections, cases of which are under-recorded, WBB Securities’ Managing Partner Steve Brozak said ahead of the approval.
H.C. Wainwright & Co projected peak annual revenue from U.S. sales of the drug at nearly $219 million before the decision.
Government estimates show around 25,000 cases of candidemia occur in the United States each year.
Candidemia infection is caused when a yeast, candida, which generally lives inside the body or skin without causing any problems, enters the bloodstream. Invasive candidiasis is when candida spreads from the bloodstream to the heart, brain, eyes or other body parts.
USFDA grants accelerated approval for Skin cancer therapy
USFDA gives approval for Calcipotriene and Betamethasone foam
USFDA gives approval for Brexpiprazole tablets
USFDA gives approval for generic Rocuronium Bromide Injection
USFDA gives approval for Prochlorperazine Maleate Tablets USP
USFDA gives approval for Ranolazine ER tablets
Drug Control Dept launches WhatsApp helpline number: Tamil Nadu
Proposal to regulate prices of non-scheduled drugs under consideration
Govt Job: For B.Pharm as Bench Chemist at CDSCO
USFDA issues Form 483 with 2 observations to Alembic, Gujarat
West Bengal notice to Pharma Industry on bio-resource use
Govt constitutes panel for PLI scheme for pharmaceuticals
Difference: Disintegration and Dissolution test in pharma industry
How to prepare SOPs in the Pharma Industry
Difference between branded and generic medicines
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
